Screener / SEC EDGAR /CIK 0001628171 /10-K filed Feb 25, 2026, compared with Feb 26, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Revolution Medicines, Inc. RVMD

Compare with peers Embed
FY2025 at a glance

Free cash flow down to -$913.7M

XBRL, from each 10-K
RevenueStatements
$0 from $0 in FY2024
FY2018FY2025
Net incomeStatements
-$1.1B from -$600.1M in FY2024
FY2018FY2025
Free cash flowStatements
-$913.7M from -$567.7M in FY2024
FY2018FY2025
EPS (diluted)Statements
$-5.95 from $-3.58 in FY2024
FY2018FY2025

The latest figures

Price and key numbers

From EDGAR
All key numbers (30)
EPS (ttm)
-9.13
Sales (ttm)
197.6M
Net income (ttm)
-1.9B
Sales growth
-
EPS growth
-
Sales Q/Q
-
Free cash flow
-1.4B
Gross margin
-
Oper. margin
-853.0%
Net margin
-946.8%
FCF margin
-729.3%
R&D / sales
-
Dividend
-
Debt/Eq
-
Curr. ratio
8.36
Cash
615.9M
Op. cash flow (ttm)
-1.4B
EBITDA
-1.2B
Quick ratio
8.36
Interest cover
-48.80
FCF after stock pay
-1.0B
Goodwill / assets
0.6%
Shares out.
216.3M
Shares Y/Y
+13.3%
Book / share
11.10
Cash / share
2.85
Sales / share
0.91
Asset turnover
0.05

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Revenue and net income, FY2018 to FY2025

Each fiscal year from its own 10-K · XBRL

Revenue 0 Net income -1.1B
FY2018 revenue 20.2M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001564590-21-010276 FY2018 net income -41.8M · NetIncomeLoss, 0001564590-21-010276 20.2M FY2018 FY2019 revenue 50.0M · RevenueFromContractWithCustomerExcludingAssessedTax, 0000950170-22-002297 FY2019 net income -47.7M · NetIncomeLoss, 0000950170-22-002297 50.0M FY2019 FY2020 revenue 43.0M · RevenueFromContractWithCustomerExcludingAssessedTax, 0000950170-23-004645 FY2020 net income -108.2M · NetIncomeLoss, 0000950170-23-004645 43.0M FY2020 FY2021 revenue 29.4M · RevenueFromContractWithCustomerExcludingAssessedTax, 0000950170-24-020145 FY2021 net income -187.1M · NetIncomeLoss, 0000950170-24-020145 29.4M FY2021 FY2022 revenue 35.4M · RevenueFromContractWithCustomerExcludingAssessedTax, 0000950170-25-027736 FY2022 net income -248.7M · NetIncomeLoss, 0000950170-25-027736 35.4M FY2022 FY2023 revenue 11.6M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001193125-26-071563 FY2023 net income -436.4M · NetIncomeLoss, 0001193125-26-071563 11.6M FY2023 FY2024 revenue 0 · RevenueFromContractWithCustomerExcludingAssessedTax, 0001193125-26-071563 FY2024 net income -600.1M · NetIncomeLoss, 0001193125-26-071563 0 FY2024 FY2025 revenue 0 · RevenueFromContractWithCustomerExcludingAssessedTax, 0001193125-26-071563 FY2025 net income -1.1B · NetIncomeLoss, 0001193125-26-071563 0 FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing.

Growth per share, FY2018 to FY2025

Earnings, book value and free cash flow for each diluted share · 10-K XBRL, every year linked to its filing

Average yearly growth
Book value per share -0.2% a year FY2020 $8.65 to FY2025 $8.58, 5 years
Fiscal year toEPS (diluted)Book value / shareFree cash flow / share
Dec 31, 2025 -$5.95$8.58-$4.81
Dec 31, 2024 -$3.58$13.50-$3.38
Dec 31, 2023 -$3.86$16.14-$3.17
Dec 31, 2022 -$3.08$8.50-$2.92
Dec 31, 2021 -$2.57$8.28-$2.11
Dec 31, 2020 -$2.01$8.65-$1.88
Dec 31, 2019 ---
Dec 31, 2018 ---

Per share means per diluted weighted-average share of the same fiscal year (the count under diluted EPS, put on today's share count after a split). Book value is shareholders' equity at the year end, including any preferred stock; free cash flow is operating cash flow less capital spending. Each tile's rate is the steady yearly growth from the first to the last year it names: the window starts at the oldest year, up to ten years back, with a value above zero.

What the balance sheet holds, per share

Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used

Net current asset value, FY2025, in dollars
  • + Current assets $2.1B
  • − All liabilities $723.2M
  • = Net current asset value $1.4B
Per share, year by year
Tangible book value, FY2025, in dollars
  • + Shareholders' equity $1.6B
  • − Goodwill $14.6M
  • − Other intangible assets $55.8M
  • = Tangible book value $1.6B
Per share, year by year

Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.

RVMD against Health care peers

Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.

Ten years, side by side
Net margin
-4.1%15.3%
-946.8%154th of 154 · median 6.8%
Return on equity
-5.2%18.5%
-77.9%139th of 144 · median 9.2%
Free cash flow margin
2.3%19.2%
-729.3%144th of 145 · median 10.0%
RVMD and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthFYGross marginttmNet marginttmROEttmFCF marginttmDebt / equitylatest
RVMD Revolution Medicines, Inc.$197.6M ---946.8%-77.9%-729.3%-
LMAT Lemaitre Vascular Inc$269.4M +13.5%72.0%23.5%14.7%24.9%-
LGND Ligand Pharmaceuticals Inc$253.8M +60.4%-20.3%5.4%35.7%1.17
GRAL GRAIL, Inc.$166.6M +17.2%--243.8%-16.6%-187.3%-
BEAM Beam Therapeutics Inc.$146.6M +120%--73.9%-11.4%-271.6%0.11
AGIO Agios Pharmaceuticals, Inc.$140.8M +48.0%93.8%-264.8%-38.1%-238.5%-
All 162 companies in the group

Profitability

  • Net margin below the peer median
    -946.8% vs 6.8%
  • Return on equity below 15%
    -77.9%
  • A profit in 0 of 8 years
Net margin, FY2018 to FY2025: -207.2% to -3768.3%

Balance sheet

  • Interest covered less than 5 times
    Operating income is -48.8× interest expense
  • Current assets cover current liabilities
    Current ratio 8.36

Cash and shareholders

  • Free cash flow positive in 0 of 8 years
    −$913.7M last year
  • Share count up over 5 years
    +131.0%
Free cash flow, FY2018 to FY2025: -286K to -913.7M

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

Income statement, balance sheet and cash flow

Statements · XBRL, each 10-K and 10-Q

From EDGAR

RVMD's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 8. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Revenue0
FY2018: 20.2MFY2019: 50.0MFY2020: 43.0MFY2021: 29.4MFY2022: 35.4MFY2023: 11.6MFY2024: 0FY2025: 0 FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Net income-1.1B
FY2018: -41.8MFY2019: -47.7MFY2020: -108.2MFY2021: -187.1MFY2022: -248.7MFY2023: -436.4MFY2024: -600.1MFY2025: -1.1B FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Free cash flow-913.7M
FY2018: -286KFY2019: -52.2MFY2020: -103.0MFY2021: -153.7MFY2022: -235.2MFY2023: -358.3MFY2024: -567.7MFY2025: -913.7M FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Free cash flow after stock pay-1.0B
FY2018: -1.1MFY2019: -55.4MFY2020: -111.9MFY2021: -174.4MFY2022: -266.4MFY2023: -420.1MFY2024: -646.9MFY2025: -1.0B FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
EPS (diluted)-5.95
FY2018: -21.24FY2019: -22.33FY2020: -2.01FY2021: -2.57FY2022: -3.08FY2023: -3.86FY2024: -3.58FY2025: -5.95 FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Diluted shares190.1M
FY2018: -FY2019: -FY2020: 54.9MFY2021: 72.8MFY2022: 80.6MFY2023: 113.1MFY2024: 167.7MFY2025: 190.1M FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025

Income statement

From EDGAR
FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue20.2M50.0M43.0M29.4M35.4M11.6M00
R&D51.1M91.8M132.3M186.9M253.1M423.1M592.2M987.3M
SG&A9.4M12.4M21.4M30.4M40.6M75.6M97.3M195.0M
Operating income-40.3M-54.1M-110.7M-188.0M-258.3M-487.2M-689.5M-1.2B
Interest expense116K106K71K12K00024.2M
Pretax income-41.8M-52.0M-108.5M-187.1M-249.1M-439.9M-600.8M-1.1B
Income tax--4.4M-371K0-420K-3.5M-753K0
Net income-41.8M-47.7M-108.2M-187.1M-248.7M-436.4M-600.1M-1.1B
EPS (diluted)-21.24-22.33-2.01-2.57-3.08-3.86-3.58-5.95
Diluted shares--54.9M72.8M80.6M113.1M167.7M190.1M
Depreciation & amortization1.6M2.3M2.6M3.1M4.0M5.0M6.6M7.8M
EBITDA-38.8M-51.8M-108.1M-184.9M-254.3M-482.2M-683.0M-1.2B
Operating margin-200.0%-108.2%-257.5%-639.7%-730.0%-4207.1%--
Net margin-207.2%-95.2%-251.6%-636.6%-703.0%-3768.3%--
Revenue growth-+148%-14.1%-31.6%+20.4%-67.3%-100%-

Balance sheet

From EDGAR

Cash flow

From EDGAR
FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow1.2M-49.6M-100.1M-147.2M-224.4M-350.6M-557.4M-897.7M
Capital spending1.5M2.6M2.9M6.5M10.8M7.7M10.3M16.0M
Free cash flow-286K-52.2M-103.0M-153.7M-235.2M-358.3M-567.7M-913.7M
Stock-based pay (added back)855K3.2M8.9M20.7M31.2M61.8M79.2M118.4M
Free cash flow after stock pay-1.1M-55.4M-111.9M-174.4M-266.4M-420.1M-646.9M-1.0B
Dividends paid--0-----
Investing cash flow-1.3M-102.0M-234.2M-142.1M-24.1M-342.6M-554.4M118.1M
Financing cash flow60.8M98.7M422.8M294.2M301.4M1.2B959.4M621.5M

Stock-based pay and leases

From EDGAR
FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Stock-based pay (expense)855K3.2M8.9M20.7M31.2M61.8M79.2M118.4M
Stock-based pay / revenue4.2%6.3%20.7%70.5%88.2%533.4%--
Operating lease cost--2.7M5.5M8.9M8.5M12.2M18.8M
Operating lease cash paid--2.6M1.5M2.4M---
Right-of-use assets--27.4M59.7M55.1M77.1M117.5M132.1M
Operating lease liabilities--32.7M66.6M64.2M87.9M135.8M158.7M
Finance lease liabilities--19K-----

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Sources

Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.

Also

Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/RVMD/export.csv") into a cell.

Next:Peers in numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.